About us

A world where as many cancers as possible can be cured and people can live a daily life rather than patients

As Japan's first radiotherapy AI startup, we at AiRato Co., Ltd. have been conducting research and development of "RatoGuide," a radiotherapy AI that is truly needed in the medical field. With the mission of "saving all cancer patients through radiotherapy," we aim to expand the possibilities of radiotherapy using AI, and to improve the outcomes and workload of cutting-edge radiotherapy. We also aim to spread the use of radiotherapy, which is a scalpel-free treatment with low patient burden and high therapeutic effect.

Company name
AiRato. Inc
Yuto Kimura (CEO)
Noriyuki Kadoya (CTO, Assistant professor of Tohoku University)
Ryo Ebina
Head Office
468-1 Aoba, Aramaki, Aoba-ku, Sendai City, Miyagi Prefecture
Aobayama Garage, Material Innovation Center, Tohoku University
March, 2022
Capital (including capital reserve)
128,000 thousand yen
Main Business
Planning and development of medical device programs


April 2021:

We were selected for Tohoku University Investment Business Business Incubation Program

February 2022:

We recieved Excellence Award and the Japan Science and Technology
Agency Award from NEDO Technology Commercialization Program

February 2022:

We were selected for the 2021 NEDO Entrepreneurs Program

March 2022:

This company was founded

June 2022:

We were selected for the 2022 NEDO Entrepreneurs Program

July 2023:

We are selected for the 2023 Miyagi Prefecture Subsidy for New Entry and New Industry Creation Support Project (Regional Innovation Creation Type)

September 2023:

We are selected for Phase 5 TRY!YAMANASHI! Demonstration Experiment Support Project

December 2023:

Started Experimental demonstration tests at the University of Yamanashi Hospital

January 2024:

Funds raised through a third-party allocation of shares in a seed round totaling 80 million yen.

April 2024:

Start of 2024 Miyagi Prefecture DX-related Startup Role Model Creation Demonstration Operations.

April 2024:

Funds raised through a third-party allocation of shares in a seed second round totaling 80 million yen.